Introduction
Progression through the mammalian cell cycle requires that gene expression is co-ordinated with the activity of cell cycle control proteins. A critical period for integrating growth regulating signals occurs during early cell cycle progression where, in the appropriate conditions, cells become committed to the division cycle. The transition from G1 into S phase is governed by a number of proteins with established roles in controlling proliferation, such as the retinoblastoma tumour suppressor protein (pRb), which is believed to be a molecule of pre-eminent importance in regulating this transition (Weinberg, 1995) , a role exerted principally through an ability to modulate the activity of transcription factors such as E2F (La Thangue, 1994; Nevins, 1992) . Indeed, E2F is a pivotal point of control in the G1/S phase transition, allowing the activity of proteins such as pRb to integrate with the activity of target genes required for cell cycle progression (La Thangue, 1994) .
The activity of pRb is regulated at the level of phosphorylation by cyclin-dependent kinases (cdks). Hypophosphorylated pRb, which is active in negative growth control and binding to E2F (Weinberg, 1995) , is progressively phosphorylated during early cell cycle through the sequential activation of cdks (Pines, 1995; Sherr, 1993) . For pRb, cyclin D/cdk4 and cyclinE/cdk2 are believed to be the predominant cdks involved in its phosphorylation (Dowdy et al., 1993; Ewen et al., 1993; Hinds et al., 1992) . In turn, the activity of cdk complexes is subject to aerent control through another group of proteins, the cdk-inhibitors (Sherr and Roberts, 1995) , which fall into two general classes that, in each case, are exempli®ed by p21
Waf1/Cip1 or p16
INK4a (Sherr and Roberts, 1995) . Members of the p21 Waf1/Cip1 group are antagonists of dierent cdk complexes, including cyclin D and E-dependent kinases (Harper et al., 1993; Xiong et al., 1993) , whereas the p16 INK4a group preferentially regulate cyclin D-dependent kinase (Serrano et al., 1993) . The cdkinhibitors impede cell cycle progression in part by preventing the phosphorylation of pRb (Koh et al., 1995; Lukas et al., 1995) .
Another important point of control during early cell cycle progression requires the p53 protein which remains in a latent state but, following genotoxic or other forms of stress, can cause cell cycle arrest or apoptosis . A primary function of p53 which is believed to correlate with cell cycle arrest relates to its role as a sequence-speci®c transcription factor (Crook et al., 1994; Pietenpol et al., 1994) for which a number of target genes have been identi®ed. One of these encodes p21
Waf1/Cip1 (El-Deiry et al., 1993; Harper et al., 1993) which, as discussed, inhibits the activity cdks and thus is believed to maintain pRb and related proteins in a hypophosphorylated growthsuppressing state. The activity of p21 Waf1/Cip1 is sucient to cause cell cycle arrest (Dulic et al., 1994; El-Deiry et al., 1993; Harper et al., 1993; Waldman et al., 1995) and, consequently, its activation likely to be important in p53-induced cell cycle arrest (Chen et al., p53 regulates other targets required for cell cycle arrest because in p21 Waf1/Cip1 knockout cells G1 arrest following irradiation is only partially abolished (Brugarolas et al., 1995; Deng et al., 1995) , whereas in p53 7/7 cells G1 arrest is completely absent (Donehower et al., 1992) .
The mechanisms involved in p53-regulated apoptosis are less clear. In some situations, transcriptional activation by p53 is dispensable for the induction of apoptosis since mutants in p53 which fail to activate transcription can still induce apoptosis (Chen et al., 1996; Haupt et al., 1995b) and p53-dependent apoptosis can occur in the presence of inhibitors of transcription and translation (Caelles et al., 1994) . Other studies have suggested a role for transcriptional activation by p53 (Attardi et al., 1996; Chen et al., 1996; Sabbatini et al., 1995) , such as for the Bax gene (Miyashita and Reed, 1995) , the product of which can antagonize the anti-apoptotic activity of Bcl-2 (White, 1996) . Thus, for p53-dependent cell cycle arrest there is a good correlation with sequence speci®c transcriptional activation, although both transcription-dependent and independent mechanisms appear to contribute to p53-dependent apoptosis.
A considerable body of evidence argues that the p53 and pRb/E2F pathways are integrated not only at the level of cell cycle arrest, via the induction of p21 Waf1/Cip1 and subsequent control of pRb activity, but through pathways which govern apoptosis. For example, mice carrying a targeted disruption in the Rb gene die in utero at about 13.5 days of gestation which, in part, is due to extensive apoptosis in a variety of tissues (Clarke et al., 1992; Jacks et al., 1992) . Similarly, in tissue culture cells inactivation of pRb through the adenovirus E1a protein induces apoptosis (Debbas and White, 1993; Sabbatini et al., 1995) , and targeting the HPV E7 protein to lens ®bre cells promotes an apoptotic outcome (Pan and Griep, 1994) . Subsequent inactivation of p53, either by co-expression of the HPV E6 protein (Pan and Griep, 1994) or targeted disruption of the p53 gene (Morgenbesser et al., 1994) , overcomes the apoptosis evident in conditions of Rb loss. Additional evidence for the integration between the p53 and E2F pathways has arisen from studies on E2F-1. Thus, although increased levels of E2F-1 can cause quiescent cells to enter S phase (Johnson et al., 1993) , it has become increasingly clear that usually this is followed by apoptosis (Qin et al., 1994; Wu and Levine, 1994) which, moreover, is enhanced by the presence of wild-type p53 (Wu and Levine, 1994) . Furthermore, several studies have shown that components within either pathway physically associate with each other (Martin et al., 1995; O'Conner et al., 1995; Sùrensen et al., 1996) . Studies such as these suggest that the apoptotic outcome caused through aberrant control of the pRb-E2F pathway is integrated with p53.
Here, we have studied p53-dependent transcriptional activation and identify p300 as a co-activator required for this process, a conclusion supported by recent studies (Avantaggiati et al., 1997; Gu et al., 1997; Lill et al., 1997; Somasundaram and El-Diery, 1997) . We show that the product of the p53 target gene p21 Waf1/Cip1 autoregulates in a positive fashion transcription through modulating the activity of the p53/p300 complex whilst negatively regulating the activity of E2F by preventing cdk-dependent phosphorylation of pRb. Consistent with a role for p21
Waf1/Cip1 in the autoregulation of p53-dependent transcription, p300 augments the ability of p53 to cause G1 arrest and, conversely, cells undergoing p53-dependent apoptosis are rescued by p300. Our data therefore suggest that the role of p300 as a co-activator for p53 contributes to an ecient G1 arrest. Moreover, we ®nd that both E2F and p53 utilize p300 as a transcriptional co-activator and that p300 enhances the apoptotic activity of E2F-1. Thus, the interaction of p300 with either p53 or E2F-1 has a profound impact on early cell cycle progression. Indeed, competition between the activation domains of p53 and E2F-1 for p300 may be instrumental in determining which physiological outcome ensues. These results suggest a critical role for p300 in orchestrating early cell cycle progression through the pathways of control mediated by E2F and p53. The p53 reporter pTG13-GL was introduced into SAOS-2 cells together with expression vectors encoding p53 (1 mg; tracks 2 ± 17), in the presence of E2F-1 (0.5 mg in tracks 3, 9, 10 and 11; 1.0 mg in tracks 4, 12, 13 and 14 or 2.0 mg in tracks 5, 15, 16 and 17), and/or pRb (1.0 mg in tracks 6, 9, 12 and 15, 6 mg in tracks 7, 10, 13 and 16, and 12 mg in tracks 8, 11, 14 and 17) . The data presented re¯ect averages from two sets of values. Throughout pCMV-bgal was included in each transfection as an internal control. The relative activity of luciferase to bgalactosidase is presented. (b) The in¯uence of E2F-1 on p53 protein level was assessed in SAOS-2 cells transfected with expression vectors encoding p53 (3 mg; tracks 1 ± 8), E2F-1 (3 mg; tracks 1 ± 4), or the control vector HA1 (3 mg; tracks 5 ± 8), metabolically labelled with 35 S-methionine as described and thereafter chased for the indicated times. The levels of p53 were resolved by immunoprecipitation. A non-transfected treatment is shown in track 9
Results

Regulation of p53-dependent transcription by E2F and pRb
To address the interplay between E2F and p53, we considered that we may gain insight into the mechanisms involved by evaluating the eects of E2F on p53-dependent transcription. Thus, we introduced wild-type p53 into the osteosarcoma-derived cell lines SAOS2 and U2OS, and thereafter monitored the activity of a p53 reporter which was dependent upon p53 transcriptional activity. The reporter of choice, pTG13-GL, contains p53 binding sites immediately upstream of the herpes virus a b c Figure 2 Regulation of p53 activity requires the E2F-1 and p53 activation domains. (a) The E2F reporter pDHFR-luc was introduced into SAOS-2 cells together with expression vectors encoding E2F-1 (0.2 mg; tracks 2 and 3) or E2F-1D413 (0.2 mg; tracks 4 and 5) together with DP-1 (2 mg; tracks 3 and 5). The data presented re¯ect averages from two sets of values. Throughout pCMVbgal was included in each transfection as an internal control, the relative activity of luciferase to b-galactosidase being presented. (b) The p53 reporter pTG13-GL was introduced into SAOS-2 cells together with expression vectors encoding E2F-1 (1 mg in track 3, and 3 mg in 4 and 7) or E2F-1D413 (1 mg in tracks 5, and 3 mg in tracks 4, 6 and 8). Values were calculated as described in (a). (c) Either the Gal4 reporter pG5-luc (1 mg; tracks 1 ± 3) or pTG13-GL (1 mg; tracks 4 ± 9) was introduced into SAOS-2 cells together with expression vectors encoding Gal4-p53 (1 mg; tracks 2 and 3), p53 (1 mg; tracks 5 and 6) or p53-VP16 (1 mg; tracks 8 and 9) in the presence of E2F-1 (2 mg; tracks 3, 6, and 9). The data presented re¯ect averages from two sets of values. pCMV-bgal was included in each transfection as an internal control, and the relative activity of luciferase to b-galactosidase activity is presented minimal thymidine kinase promoter together with the SV40 enhancer driving the luciferase gene, and in SAOS2 possessed minimal activity in the absence of p53 but responded favourably to exogenous wild-type p53 (for example Figure 1a , compare tracks 1 and 2); similar data were obtained from transfection studies in U2OS cells.
To establish the in¯uence of the E2F pathway on p53, we introduced increasing levels of E2F-1 or pRb and thereafter assayed p53 activity. Increased levels of E2F-1 caused a concomitant decline in the transcriptional activity of p53 (Figure 1a , compare tracks 2 , 3, 4 and 5) whereas, in contrast, increased levels of pRb stimulated p53-dependent transcription (Figure 1a , compare tracks 2 ± 6, 7 and 8). Further support for this idea was provided by co-expressing E2F-1 in the presence of pRb. In these conditions, pRb antagonised the eects of E2F-1 so that a reduction in p53-dependent transcription was no longer apparent ( Figure 1a , compare tracks 3 ± 9, 10 and 11). At the same time, the stimulation of p53 activity by pRb was less when co-expressed with E2F-1 (Figure 1a , compare tracks 6 ± 8 to 9, 10 ± 11), and a titration of E2F-1 levels in the presence of pRb provided additional evidence for this view, since upon increased levels of E2F-1 there was a proportional decline in the transcriptional activity of p53 ( Figure 1a , compare tracks 9 ± 11 to 12 ± 17). Thus, the transcriptional activity of p53 is in¯uenced by the levels of E2F-1 and, moreover, the presence of pRb overcomes this eect, suggesting that the p53 and pRb/E2F pathways of growth control are functionally integrated.
Certain control treatments were performed to establish the speci®city of E2F-1 on p53. For example, the eects on p53 transcriptional activity were dependent upon exogenous p53 since without p53 no changes in activity on the pTG13-GL reporter in the presence of E2F-1 or pRb were apparent (data not shown). The level of exogenous p53 protein was not aected by co-expression of E2F-1 (Figure 1b , compare tracks 1 ± 4 with 5 ± 8) and, further, each transfection treatment was internally controlled to rule out general eects of p53, E2F-1 or pRb on the transcription apparatus (see Materials and methods). Having established the speci®city of the E2F-1 eect upon p53-dependent transcription, we went on to investigate the mechanism involved.
The regulation of p53 activity requires the E2F-1 and p53 activation domains An outcome of the interaction between pRb and E2F-1 is the inactivation of the C-terminal transcription activating domain, which is integrated with the domain recognised by pRb (Flemington et al., 1993; Helin et al., 1993; Kaelin et al., 1992) . Since the regulation of p53 activity by E2F-1 was overcome by pRb ( Figure 1a ), we reasoned that the E2F-1 activation domain may be in¯uential in regulating p53 activity. To assess this possibility, a mutant E2F-1 protein which lacks the C-terminal activation domain, due to truncation up to amino acid residue 413 (E2F-1D413), was studied. As expected E2F-1D413 had greatly a b
Figure 3 p300 rescues E2F-1 inactivated p53 and enhances the transcriptional activity of p53 and E2F-1. (a) The p53 reporter pTG13-GL was introduced into SAOS-2 cells together with expression vectors encoding p53 (1 mg; tracks 2 ± 7) in the presence of E2F-1 (2 mg; tracks 3, 4 and 5) with p300 (6 and 12 mg in tracks 4 and 5, and 6 and 7 respectively). The data presented re¯ect averages from two sets of values. Throughout pCMV-bgal was included within each transfection as an internal control, and the relative activity of luciferase to b-galactosidase presented. (b) The E2F reporter pDHFR-luc was introduced into SAOS-2 cells together with expression vectors encoding E2F-1 (0.2 mg; tracks 2, 3 and 4) together with p300 (2 and 10 mg in tracks 3 and 4, and 5 and 6 respectively). Values were calculated as described in (a) reduced ability to stimulate the transcription of the E2F-responsive DHFR promoter in the absence or presence of DP-1 (Figure 2a , compare tracks 1 ± 5).
When assessed for its eect upon p53 activity, and in contrast to wild-type E2F-1, E2F-1D413 failed to cause a reduction but rather increased p53-dependent transcription ( Figure 2b , compare tracks 3 and 4 with 5 and 6), the reasons for which remain to be explored. Thus, the integrity of the transcriptional activation domain is necessary for the reduction in p53 activity by E2F-1. Since the regulation of p53 required the E2F-1 transcriptional activation domain, we reasoned that the activation domain in p53 may be involved. Therefore, we tested whether a fusion protein containing the N-terminal transcription activation domain of p53 was sensitive to the eects of E2F-1. In a similar fashion to wild-type p53, the activity of Gal4-p53 was reduced by E2F-1 (Figure 2c , compare tracks 2 and 3).
It was important to determine the speci®city of the eect of E2F-1 on p53. To this end, we studied whether E2F-1 caused a reduction in the activity of other transcription activation domains. A variety of activation domains were assessed as Gal4 fusion proteins, of which the p53 activation domain was by far the most sensitive (data not shown). Further, the inactivation of p53 was not caused through general eects, such as protein stability, because a hybrid protein in which the VP16 activation domain was fused to the wild-type p53 protein became far less sensitive to the eects of E2F-1 (Figure 2c , compare tracks 5 and 6 with 8 and 9).
p300 relieves the inactivation of p53 by E2F-1
The results so far raise the possibility that competition for a shared transcription target is responsible for the eect of E2F-1 on p53-dependent transcription. The potential identity of such a molecule was addressed by determining which proteins, when co-expressed with E2F-1 and p53, relieved the repression of p53 activity. Expression of the co-activator p300 (Shikama et al., 1997) , a molecule previously implicated in E2F-1 mediated transcriptional activation (Trouche et al., 1996) , eectively relieved the repression of p53 ( Figure  3a , compare tracks 3, 4 and 5) and enhanced in p53-dependent transcription in the absence of E2F-1 (Figure 3a , compare tracks 3, 4, 5, 6 and 7). These data argue that p300 functions as a transcriptional coactivator for p53 and, further, suggest that a limiting level of p300 is in part responsible for the inactivating eect of E2F-1 on p53.
To con®rm that p300 can provide a co-activator function to E2F-1, we assayed the eect of p300 and E2F-1 on the DHFR promoter. As expected, coexpression of p300 enhanced transcriptional activity in an E2F-1-dependent fashion ( Figure 3b , compare tracks 2 ± 6). Thus, the combined conclusion from these studies suggests that p300 is a shared co-activator utilized by p53 and E2F-1 and therefore a likely target involved in mediating the eect on p53 by E2F-1. That co-expression of pRb relieved the eect of E2F-1 on p53 ( Figure 1a ) is consistent with this result since pRb inactivates the transcriptional activity of E2F-1 (Flemington et al., 1993; Helin et al., 1993) . p300 physically associates with p53 and E2F-1
Having established a functional relationship between p53 and p300, and E2F-1 and p300, we wished to determine if this was due to the direct physical interaction between each pair of proteins. To test this possibility we used a p300 derivative, pG4-p300 611 ± 2284 , in which the region between amino acid residue 611 and 2284 is fused to the Gal4 DNA binding domain. We chose pG4-p300 611 ± 2284 for these studies because it is eciently expressed in a variety of mammalian cells (data not shown). Extracts were prepared from U2OS cells expressing pG4-p300 611 ± 2284 and the interaction between p53 and pG4-p300 611 ± 2284 assessed using a binding assay where in vitro translated and radiolabelled p53 or the control luciferase was added to the U2OS cell extract and the association with p300 determined by immunoprecipitation using an antiGal4 antiserum (Figure 4a , compare tracks 5 and 6). An interaction between p53 and pG4-p300 611 ± 2284 was detected but not between luciferase ( Figure 4a , compare tracks 3 and 4) suggesting a speci®c association between p53 and p300. The detection of p53 in the immunoprecipitate was dependent upon immunoprecipitation since in the absence of the anti-Gal4 antiserum p53 was no longer apparent ( Figure 4a , compare tracks 2 and 4).
To con®rm that p300 and p53 can physically associate in vivo, we co-expressed G4-p300 611 ± 2284 and p53 in U2OS cells, immunoprecipitated with anti-Gal4 followed by immunoblotting with anti-p53 monoclonal antibody 421. Again, p53 was speci®cally detected in the p300 immunocomplex ( Figure 4b , compare tracks 2, 3 and 4) establishing that p300 and p53 can physically associate in mammalian cells.
Further evidence was obtained by taking a two-hybrid approach in U2OS cells in which G4-p300 611 ± 2284 , which is transcriptionally inactive in these conditions, was used as the`bait' (Figure 4c , compare tracks 2 ± 7). For the`prey', we fused wildtype p53 to VP16 which, when expressed with the p300 hybrid, caused a signi®cant increase in the transcriptional activity of the reporter pG5-luc ( Figure 4c , compare tracks 7 ± 9). Transcription was dependent upon the hybrid p53-VP16 protein since neither p53 nor VP16 caused a similar increase ( Figure 4c , compare tracks 8, 9 and 10). Importantly, the eect of p53-VP16 required p300 protein sequence as there was no apparent eect on the Gal4 DNA binding domain alone ( Figure 4c , compare tracks 2 ± 5). Similar data from the two-hybrid assay were observed in SAOS2 cells (data not shown).
An immunoprecipitation strategy was used to determine if E2F-1 and DP-1 associate with p300. After immunoprecipitating G4-p300 611 ± 2284 , immunoblotting was performed with antisera against either E2F-1 or the haemagglutin (HA) epitope to detect the DP-1 protein. Both E2F-1 and DP-1 could associate with p300 since either protein co-immunoprecipitated with G4-p300 611 ± 2284 ( Figure 5a , compare tracks 1 ± 3 and 5 ± 7).
We con®rmed the interaction by taking the twohybrid approach in which G4-p300 611 ± 2284 was assessed for an interaction with GAD-E2F-1, a construct in which the Gal4 activation domain was fused to E2F-1. There was a signi®cant increase in activity when pG4-p300 611 ± 2284 and GAD-E2F-1 were expressed together (Figure 5b , compare tracks 6 and 8). The enhanced transcription was speci®c for the p300 (Figure 5b , compare tracks 4 and 8) and E2F-1 (Figure 5b , compare tracks 8 and 9) sequence in each hybrid protein. The overall conclusion from the biochemical and two-hybrid based assays strongly suggests that p53 and E2F-1 can form a stable physical complex with p300.
To con®rm the interpretation from the earlier experiments, namely, that the activation domain of p53 and E2F-1 is a target for p300, we studied in the two-hybrid assay the interaction between a mutant p53 protein which lacked the N-terminal activation domain, p53D159-VP16, and a mutant E2F-1 protein which lacked the C-terminal activation domain, E2F-1D413-VP16. Neither of the mutant hybrid proteins The expression vector encoding G4-p300 611 ± 2284 was introduced into U2OS cells and after 48 h harvested as described. Either in vitro translated 35 S-methionine-labelled luciferase (tracks 1 and 3) or p53 (tracks 2 and 4) was added to the extract, thereafter immunoprecipitated with the anti-Gal4 antiserum and further resolved by gel electrophoresis. Tracks 5 and 6 show the input in vitro translates for luciferase (track 5) or p53 (track 6). (b) The expression vector encoding G4-p300 611 ± 2284 (tracks 2, 3 and 4) together with either p53 (track 3) or p53-VP16 (track 4) was introduced into U2OS cells and after 48 h immunoprecipitation performed with the anti-Gal4 antiserum (tracks 2, 3 and 4) followed by gel electrophoresis. Immunoblotting was performed with the p53 monoclonal antibody 421. Note that the common band present across tracks 2, 3 and 4 results from non-speci®c activity for the immunoglobulin used in the ®rst immunoprecipitation which obscures the wild-type p53 polypeptide in track 3 (data not shown). Track 1 shows the standard molecular weight polypeptides. The p53-VP16 polypeptide is indicated. (c) Two-hybrid assay in U2OS cells or SAOS2 cells (data not shown) where the Gal4 reporter pG5-luc was introduced together with expression vectors pG4 encoding either the Gal4 DNA binding domain (1 mg; tracks 2, 3, 4 and 5) or pG4-p300 611 ± 2284 (1 mg; tracks 7, 8, 9 and 10) together with either wild-type p53 (5 mg; tracks 3 and 8), p53-VP16 (5 mg; tracks 4 and 9) or VP16 (5 mg; tracks 5 and 10). The data presented re¯ect averages from two sets of values. Throughout pCMV-bgal was included within each transfection as an internal control, and the relative activity of luciferase to b-galactosidase presented Figure 5 p300 physically associates with E2F-1 and DP-1. (a) The expression vector encoding G4-p300 611 ± 2284 (20 mg; tracks 1, 2, 3, 5, 6 and 7) together with either E2F-1 (20 mg; tracks 1 and 5) or HA-DP-1 (20 mg; tracks 2 and 6) were introduced into U2OS cells and after 48 h immunoprecipitation performed with the anti-Gal4 antiserum followed by gel electrophoresis. Immunoblotting was performed with either anti-E2F-1 (tracks 1 ± 4) or anti-HA (tracks 5 ± 8) as described in Materials and methods. Note that the common band present across tracks 1 ± 3, and 5 ± 7, results for non speci®c activity for the immunoglobulin used in the immunoprecipitation. (b) Two-hybrid assay in U2OS cells where the Gal4 reporter pG5-luc was introduced together with expression vectors pG4 (1 mg; tracks 2, 3, 4 and 5) or pG4-p300 611 ± 2284 (1 mg; tracks 6, 7, 8 and 9) together with either wild-type E2F-1 (5 mg; tracks 3 and 7), pGAD-E2F-1 (5 mg; tracks 4 and 8) or GAD (5 mg; tracks 5 and 9). The data presented re¯ect averages from two sets of values. Throughout pCMV-bgal was included within each transfection as an internal control, and the relative activity of luciferase to b-galactosidase presented. (c) Two-hybrid assay in U2OS cells or SAOS2 cells (data not shown) where the reporter pG5-luc was introduced together with expression vectors for pG4-p300 611 ± 2284 (1 mg; tracks 2 ± 6), p53-VP16 (5 mg; track 3), p53D159-VP16 (5 mg; track 4), E2F-1-VP16 (5 mg; track 5) or E2F-1D413-VP16 (5 mg; track 6). The data presented re¯ect averages from two sets of values, and throughout pCMV-bgal was included as an internal control were capable of interacting with pG4-p300 611 ± 2284 compared to the wild-type hybrid protein (Figure 5c , compare tracks 3 and 4, and 5 and 6); similar twohybrid assay results were obtained from SAOS2 cells (data not shown). Furthermore, the co-expression of p300 with p53 or E2F-1 failed to in¯uence the levels of either protein (Figure 6a and b) , consistant with the idea that p300 enhances the transcriptional activity of p53 and E2F-1. Thus, we conclude that the interaction of p300 with either p53 or E2F-1 is mediated through binding to the activation domain.
p21 enhances p53-dependent transcription by regulating the p53/p300 interaction
The p21
Waf1/Cip1 gene is transcriptionally activated by p53, containing functional p53 binding sites within its transcriptional control region (El-Deiry et al., 1993; Macleod et al., 1995) . We were interested to test the idea that p21
Waf1/Cip1 may act in an autoregulatory fashion upon the p53/p300 interaction and thereby stimulate transcription. To assess this possibility, we used the two-hybrid assay between G4-p300 611 ± 2284 and p53-VP16 (Figure 7a ). Under conditions in which there was a clear interaction between G4-p300 611 ± 2284 and p53-VP16 (Figure 7a , compare tracks 2 and 3), the levels of p21 was dependent upon the co-expression of p300 and p53 because there was only a marginal eect on G4-p300 611 ± 2284 by p21 Waf1/Cip1 (Figure 7a , compare track 2 with 7, 8 and 9). These data indicate that co-expression of p21
Waf1/Cip1 enhances the activity of the p53/p300 interaction.
The conclusion that p21 Waf1/Cip1 enhances the interaction between p53 and p300 rests on the two-hybrid assay. Therefore, it was necessary to demonstrate the eect of p21
Waf1/Cip1 on the activity of transcriptionally active wild-type p53. Increasing levels of p21 Waf1/Cip1 were introduced together with wild-type p53 and p53-dependent transcription assayed. In the presence of p21 Waf1/Cip1 there was a marked stimulation of p53 transcriptional activity (Figure 7b , compare tracks 2, 3, 4 and 5), an eect dependent upon the presence of wild-type p53 (Figure 7b , compare tracks 1 with 6, 7 and 8). We conclude that the expression of p21 Waf1/Cip1 causes an increase in the transcriptional activity of wild-type p53, and that a likely mechanism based on the earlier results is through potentiating the activity of the p53/p300 co-activator complex. p300 is required for the activation of Waf1/Cip1
To investigate the role of p300 in the regulation of cellular genes, we studied the p53-responsive promoter taken from Waf1/Cip1 (El-Deiry et al., 1993). The expression of the adenovirus E1a protein caused a signi®cant reduction in transcriptional activity ( Figure  8a , compare tracks 1 and 2), consistent with the ability of E1a to sequester p300 (Arany et al., 1995) . In contrast, a mutant E1a protein that lacks the Nterminal p300 binding domain failed to reduce the transcriptional activity of Waf1/Cip1 (Figure 8a , compare tracks 1 and 3), consistent with a role for p300 in regulating the transcription of Waf1/Cip1. Conversely, in these experimental conditions the promoter taken from Bax, another p53 responsive gene (Miyashita and Reed, 1995) , was only marginally aected by E1a (Figure 8a , compare tracks 4 and 5), suggesting that the role of p300 in the transcription of Bax was less compared to its signi®cant role in regulating the transcriptional activity of Waf1/Cip1.
To identify the region in p300 that physically interacts with p53, a panel of hybrid proteins were prepared in which dierent domains of p300 were fused to the Gal4 DNA binding domain and co-expressed with the hybrid protein p53-VP16 (Figure 8b ). The p53 interaction domain mapped to the C-terminal region of p300, speci®cally within the sequence from residue 1572 ± 1903, since co-expression of pG4-p300 1572 ± 1903 with p53-VP16 caused a six-fold induction of transcription (Figure 8b) . A similar level of induction was apparent with pG4-p300 1572 ± 2284 but not for pG4-p300 611 ± 1572 or pG4-p300 1302 ± 1572 (Figure 8b ). Thus, p300 contains a C-terminal domain which is dedicated to a functional interaction with p53. Signi®cantly, this region in p300 is known to bind to the E1a protein (Eckner et al., 1996) , suggesting that a competitive mechanisms may account for the inactivation of p53-dependent transcription by E1a through the sequestration of p300. The expression vector encoding E2F-1 (2 mg) was introduced into U2OS cells together with increasing levels of the p300 vector (1, 3, 6, 9 and 12 mg) as indicated. Extracts were prepared and immunoblotted with the KH95 monoclonal antibody, and M shows the standard molecular weight markers. A tenfold induction of E2F-1 was apparent in transfected cells
Physiological consequences of p300 interacting with p53 and E2F
The induction of transcription of the gene encoding p21 Waf1/Cip1 by p53 correlates with cell cycle arrest by p53 (Chen et al., 1996; El-Deiry et al., 1993; Macleod et al., 1995) 
and the expression of p21
Waf1/Cip1 is sucient to prevent cell cycle progression (Dulic et al., 1994; Waldman et al., 1995) . We reasoned that the ability of p300 to interact with and enhance the transcriptional activity of p53 may facilitate cell cycle arrest.
To test this idea we introduced p53 into asynchronous cultures of SAOS2 cells and monitored the proportion of transfected cells in G1, S and G2/M, both in the presence and absence of co-expressed p300 (Figure 9 ). Transfected cells were identi®ed by the expression of the cell surface protein CD20 and subsequent staining with an anti-CD20 monoclonal antibody, and the percentage of cells in each phase of the cell cycle measured after treatment with propidium iodide.
We performed the¯ow cytometry experiments in SAOS2 where the introduction of p53 caused an accummulation of cells in G1, usually resulting in an increase in G1 size of about 20% ( Figure 9a) ; similar results were obtained in U2OS and 3T3 cells (data not shown). Under these conditions we expressed p300 either alone or together with p53. When p300 was coexpressed with p53 there was a marked increase in the proportion of cells in G1, compared to p53 alone ( Figure 9a) ; p300 had little eect in the absence of p53.
We conclude that p300 can facilitate cell cycle arrest by p53, and that a possible mechanism involves increased transcription of p53 target genes, such as the p21 Waf1/Cip1 gene, as a result of p300 enhancing the transcriptional activity of p53.
Next, we explored the role of p300 in apoptosis. For this, we used SAOS2 or U2OS cells that had been cultured in serum starvation conditions, condition favour that apoptosis (White, 1996) . The data presented were derived from SAOS2 cells, although very similar results were obtained from U2OS cells (data not shown). Three assays were used to measure the level of apoptotic cells, namely TUNEL,¯ow cytometry (cells with sub-genomic levels of DNA) and the cell death detection assay (see Materials and methods). Data derived from TUNEL assays are shown (Figure 9b and summarized in Table 1 ), similar conclusions being made from the other two assays.
In SAOS2 cells, the introduction of wild-type p53 caused a signi®cant level of apoptosis ( Figure 9b and Table 1 ) consistant with previous reports (Chen et al., 1996) . When p300 was assessed in the same cells, little dierence was apparent from the untreated cells, although the introduction of p53 together with p300 sign®cantly reduced the proportion of apoptosing cells (Table 1) . Thus, the ability of p53 to favour apoptosis or cell cycle arrest is in¯uenced by the level of p300.
We went on to study the eect of E2F-1 in SAOS2 cells. Interestingly, E2F-1 when expressed alone caused signi®cant levels of apoptosis ( Figure 9b and Table 1) indicating that the apoptotic activity of E2F-1 is not a b Figure 7 p21 Waf1/Cip1 enhances the activity of the p53/p300 complex and p53-dependent transcription. (a) Two-hybrid assay in SAOS-2 cells where the Gal4 reporter pG5-luc was introduced together with pG4-p300 611 ± 2284 (1 mg; tracks 2 ± 9) and p53-VP16 (5 mg; tracks 3 ± 6) in the presence and increasing levels of p21 Waf1/Cip1 (1 mg in tracks 4 and 7, 5 mg in tracks 5 and 8 and 10 mg in tracks 6 and 9). The data presented re¯ect averages from two sets of values. Throughout pCMV-bgal was included within each transfection as the internal control, and the relative activity of luciferase to b-galactosidase presented. (b) The p53 reporter pTG13-GL was introduced into SAOS-2 cells together with expression vectors encoding p53 (1 mg; tracks 2 ± 5) in the presence of increasing levels of p21 Waf1/Cip1 (1 mg in tracks 3 and 6, 5 mg in tracks 4 and 7 and 10 mg in tracks 5 and 8). Values were calculated as described in (a) absolutely dependent upon the presence of wild-type p53. In these conditions, the apoptotic activity of E2F-1 was enhanced by p300 ( Figure 9b and Table 1 ), in contrast to the eect of p300 on p53 where it increased the eciency of p53-dependent cell cycle arrest. Further, a clear stimulation in the proportion of apoptotic cells was apparent when E2F-1 and p53 were expressed together ( Figure 9b and Table 1 ), a result which corroborates earlier reports (Qin et al., 1994; Wu and Levine, 1994) . That limiting levels of p300 may inpart be responsible for this enhanced apoptosis was suggested from introducing p300 into cells undergoing E2F-1/p53-dependent apoptosis, upon which the level of apoptosis was signi®cantly reduced (Figure 9b and Table 1 ). Thus, as observed earlier for the eect of p300 on p53-dependent apoptosis, p300 could partially rescue E2F-1/p53-dependent apoptosis.
Overall, these results suggest that p300 plays a critical role in regulating the early cell cycle, speci®cally in in¯uencing the contrasting outcomes of cell cycle arrest and apoptosis. Discussion p300 in the control of E2F and p53-dependent transcription A considerable body of research evidence has suggested that the pathways regulated by E2F and p53 are integrated in a way that allows p53 to sense aberrant control of E2F activity. A particularly clear example of this phenomenon relates to the induction of p53-dependent apoptosis in conditions where E2F-1 is a b Figure 8 (a) p300 is required for the activation of Waf1/Cip1. The promoter from either Waf1/Cip1 or Bax fused to luciferase, referred to as pWWP (tracks 1, 2 and 3) and pBax (tracks 4, 5 and 6) respectively, was introduced into U2OS cells together with expression vectors for either wild-type E1a (0.5 mg; tracks 2 and 5) or E1aD2-36 (0.5 mg; tracks 3 and 6). The data presented re¯ect averages from two sets of values, with pCMV-bgal included throughout as the internal control. (b) A C-terminal domain in p300 dedicated to an interaction with p53. Two-hybrid assay performed in U2OS cells where the Gal4 reporter pG5-luc was introduced together with expression vectors encoding the indicated Gal4-p300 hybrids (1 mg) with or without p53-VP16 (4 mg). The data presented re¯ect averages from two sets of values normalized to the activity of the internal control pCMV-bgal expressed at high levels in tissue culture cells (Qin et al., 1994; Wu and Levine, 1994) . Other studies, including those where the expression of viral oncoproteins which inactivate pRb occurs in de®ned cells, such as lens ®bre cells (Pan and Greip, 1994) , and the targetted disruption of Rb where the apoptosis is dependent upon p53 (Morgenbesser et al., 1994) , support this general idea.
In this study, we have identi®ed a mechanism which can explain the functional interplay between E2F and p53 and which may, in part, in¯uence the physiological outcome in conditions of aberrant levels of E2F. A a -+ p300 -p53 E2F-1 p53/E2F-1 b Figure 9 Eect of p300 on cell cycle arrest and apoptosis. (a) Flow cytometry was performed on asynchronous cultures of SAOS2 cells transfected with the CD20 expression vector (10 mg) together with p53 alone or p53 and p300 together. 15 mg of each expression vector was introduced, the total amount of DNA for each treatment being equivalent and made up with empty vector. Transfected cells were identi®ed by staining with anti-CD20 and the cell cycle pro®le was assessed by staining with propidium iodide. The percentage change compared to the control treatment (CD20 expression vector alone) is shown. The data show a representative example from at least four dierent data sets. (b) The eect of p300 on p53-dependent and independent apoptosis was assessed in both SAOS2 and U2OS cells transfected in conditions of serum starvation (see Materials and methods) as indicated with 4 mg of p53 and/or E2F-1 expression vector in the absence or presence of the p300 expression vector, the total amount being made up with empty vector. Results for SAOS2 cells are shown when assayed by TUNEL assay (left hand side of each treatment) and, for comparison, a DAPI stain of the same ®eld of cells. The level of apoptosis for each treatment is summarized in Table 1 mechanism was suggested when we observed that coexpression of E2F-1 caused a concomitant reduction in p53-dependent transcription, an eect which was overridden by co-expression of pRb. This, combined with the evidence that the trans activation domains of E2F-1 and p53 were involved, raised the possibility that competition for a rate limiting transcription target may be responsible for the down-regulation of p53. The p300 protein, which possesses the properties of a transcriptional co-activator and is involved in regulating the activity of a variety of sequence speci®c transcription factors (Shikama et al., 1997) , overcame the down-regulation of p53 and, moreover, enhanced the activity of both E2F-1 and p53-dependent transcription, an eect dependent on a physical association between the trans activation domain of each protein and p300. Thus, our data strongly suggest that the reduced level of p53 transcriptional activity in the presence of E2F-1 is exerted through each trans activation domain competing for the p300 co-activator. That co-expression of pRb neutralized the eect of E2F-1 on p53 makes good sense in the light of the regulation of the E2F-1 activation domain by pRb (Flemington et al., 1993; Helin et al., 1993; Kaelin et al., 1992) . Indeed, it is possible that other studies where an E2F-dependent reduction in p53 transcriptional activity has been reported (O'Connor et al., 1995) could involve a similar mechanism as the competition for p300 proposed in the present study.
It is interesting that p300 functions as a co-activator for p53 and E2F-1. The p300 family of proteins, which in mammalian cells includes one other molecularly characterized member called CBP, was de®ned by studies on the mechanisms through which the oncogene products of DNA tumour viruses subvert normal cellular growth control (Arany et al., 1995) . Within the adenovirus E1a protein, p300 interacts with a domain which is required for E1a to exert a range of biological eects on cells, such as, the induction of DNA synthesis and apoptosis (Moran, 1993) . Recent evidence indicates that the p300 family is responsible for regulating the activity of a range of DNA sequencespeci®c transcription factors, particularly those which function in dierentiation (Shikama et al., 1997) . Further reports have connected p300 genes with diseases such as cancer where they can become mutated and possess the properties of tumour suppressor genes (Muraoka et al., 1996) .
Positive autoregulation of p53-dependent transcription by p21
Waf1/Cip1
Cell cycle arrest mediated by p53 is thought to rely on the ability of p53 to directly activate the transcription of target genes, such as p21 Waf1/Cip1 , which functions as an inhibitor of cyclin-dependent kinases (Chen et al., 1996; El-Deiry et al., 1993; Harper et al., 1993; Macleod et al., 1995) and thus likely occurs through the inactivation of G1 cdk activity and the maintenance of pRb and related proteins in a hypophosphorylated state. Our results de®ne a further level of control in the regulation of p21 Waf1/Cip1 , exerted through a positive autoregulatory feedback mechanism whereby p21 Waf1/Cip1 enhances the transcriptional activity of the p53/p300 co-activator complex. Although the precise mechanism of action remains to be determined, this eect of p21
Waf1/Cip1 suggests that the activity of the p53/ p300 co-activator complex is in¯uenced in a negative fashion by cdk phosphorylation. The recent demonstration that p300 associates with cyclin E/cdk2 (Perkins et al., 1997) is consistent with this idea.
A recurring theme in the control of the cell cycle is that of positive autoregulation, which is believed to provide a mechanism for enabling the rapid accummulation of regulatory proteins involved in mediating cell cycle transitions. Numerous examples are known, such as in Saccharomyces cerevisiae where a positive autoregulatory feedback control on transcription by the G1 cyclins favours the rapid induction of cdk activity and thus progress into S phase (Johnston, 1992) . Similarly, the mammalian E2F-1 gene is autoregulated by E2F activity (Johnson et al., 1994) and the product of the cyclin E gene, which is regulated by E2F, may positively regulate transcription of its own gene by antagonizing the repressive eects of pRb and related proteins (Botz et al., 1996) . The autoregulation of p53/p300 activity by p21
Waf1/Cip1 provides another interesting example of such a mechanism which likely assists the rapid accummulation of p21 Waf1/Cip1 , thus augmenting cell cycle arrest. Since it is widely believed that p53 responds to environmental stress, a rapid cell cycle arrest clearly is a desirable response.
p300 in the control of apoptosis
Our conclusions relating to the biological signi®cance of the interaction between p53 and p300 suggest that it is critical in determining the physiological consequence of p53 induction. Thus, p300 can enhance the ability of p53 to cause G1 arrest and, moreover, reduce the proportion of cells undergoing p53-dependent apoptosis. These observations are consistent with a role for p300 as a p53 co-activator in the transcription of p21 Waf1/Cip1 , and in turn suggest that p53 induction and limiting levels of p300 may be a signal which causes cells to enter apoptosis. It is known that transcriptionally inactive p53 proteins can induce apoptosis (Caelles et al., 1994; Chen et al., 1996; Haupt et al., 1995b) whereas transcriptional activity correlates with cell cycle arrest (Crook et al., 1994) . Further evidence suggests that the level of p53 may dictate the cellular A summary of the level of apoptosis caused by each treatment in SAOS2 cells. The percentage of apoptotic cells was determined by counting the number of TUNEL positive cells compared to the total cells examined from DAPI staining. The numbers represent the average from several independent experiments. The expression of transfected plasmids was con®rmed and the transfection eciency established by indirect immuno¯uorescence (data not shown) response, with low levels of p53 causing cell cycle arrest and high levels of apoptosis (Chen et al., 1996) . Given the data presented in this study, it is possible at high levels of p53 that p300 becomes limiting which, suggested by the data presented here, provides an apoptotic signal. Further, the induction of p53-dependent apoptosis by adenovirus E1a requires the integrity of the N-terminal p300-binding domain (Querido et al., 1997) and thus is likely to be mediated by a transcriptionally compromised form of p53. Of course, some studies have suggested that transcription-dependent mechanisms are involved in p53-dependent apoptosis, and by no means is our study incompatible with this view. For example, the Bax gene has been implicated as a direct target for p53 (Miyashita and Reed, 1995) . However, although Bax 7/7 thymocytes fail to respond to certain apoptotic stimuli, they are not de®cient in p53-dependent DNA damage induced apoptosis (Knudson et al., 1995) . It is likely therefore that p53 can in¯uence apoptosis through dierent mechanisms. The model proposed in this study suggesting that apoptosis occurs in conditions of p53 induction with limiting levels of p300 may account for one such mechanism. However, we note that other recent studies have suggested that p300 plays a positive role in regulating p53-dependent apoptosis (Avantaggiati et al., 1997; Lill et al., 1997; Somasundaram and El-Deiry, 1997) and, although further experiments are required to clarify these issues, it is possible that the dependence of p53 activity on p53 concentration is a contributory factor.
Although apoptosis is enhanced when p53 and E2F-1 are expressed together, nevertheless E2F-1 alone was capable of inducing apoptosis in p53 7/7 tumour cells, suggesting that p53-dependent and independent mechanisms contribute towards E2F-1 induced apoptosis (this study and Hsieh et al., 1997; Phillips et al., 1997) . In p53 7/7 cells, the co-expression of E2F-1 and p300 enhanced apoptosis, in contrast to the eect of p300 in cells expressing p53 and E2F-1 when there was a signi®cant decrease in the proportion of apoptotic cells. Although there was not a complete rescue from apoptosis, this result is nevertheless consistent with the proposed model that limiting levels of p300 favour p53-dependent apoptosis. Indeed, we would have predicted that p300 could not completely rescue cells from apoptosis through the enhanced activity of p53 because, clearly, in SAOS2 cells E2F-1 can induce apoptosis in the absence of p53. Moreover, it is noteworthy that the partial rescue of apoptosis by p300 is compatible with earlier reports indicating that p53-mediated apoptosis can be overcome by pRb (Haupt et al., 1995a) since, as explained, the presence of p300 will directly favour the maintenance of hypophosphorylated pRb.
A central role for p300 in early cell cycle control That p300 functions as a co-activator involved with E2F and p53-dependent transcription and can in¯uence the physiological consequence of p53 induction suggests that p300 plays a central role in co-ordinating a b c Figure 10 Model for cell cycle control by p300. It is envisaged that during normal cell cycle progression (a) p53 remains in a latent state and that p300 functions as a co-activator for transcription factors such as E2F-1. Upon activation and cell cycle arrest by p53 (b), p300 functions as a co-activator for p53-dependent transcription, such as in the activation of the p21 Waf1/Cip1 gene. The activity of the p53/p300 co-activator complex is enhanced by p21
Waf1/Cip1 through a positive autoregulatory feedback loop whilst the activity of E2F declines due to the presence of hypophosphorylated pRb. For (c), in conditions which are inappropriate for cell cycle progression aberrantly high levels of E2F compete for p300, leaving p53 in a transcriptionally compromised state. It is envisaged that this form of p53, which may also arise upon increased levels of p53, together with E2F provides a signal for apoptosis early cell cycle events. The results presented in this study, together with the documented role of p53-dependent transcription in cell cycle arrest, are consistent with a model in which the productive interaction between p53 and p300 and consequent activation of target genes like p21
Waf1/Cip1 is important in controlling cell cycle arrest. However, we note that a p21
Waf1/Cip1 de®ciency does not completely abbrogate G1 arrest due, for example, to irradiation (Brugarolas et al., 1995; Deng et al., 1995) whereas in p53 7/7 knock out animals G1 arrest is completely absent (Donehower et al., 1992) . Thus, p53 likely has other targets in addition to p21
Waf1/Cip1 which confer cell cycle arrest. Relating our results to the model, we propose that in normal cell cycle conditions E2F utilises co-activator p300 in the regulation of genes required for the G1/S phase transition (Figure 10a ), circumstances in which p53 remains in a latent and non-active state. When the induction of p53 causes cell cycle arrest, for example, in response to genotoxic stress, we suggest that p53 activates transcription in concert with p300 as a coactivator (Figure 10b ). Positive autoregulation by p21
Waf1/Cip1 enhances the transcriptional activity of the p53/p300 co-activator complex, thus facilitating the rapid induction of p21 Waf1/Cip1 , and thereafter cell cycle arrest. At the same time, the inhibition of cdk activity will retain pRb and related proteins in a hypophosphorylated state and thus, by virtue of excluding the E2F-1 activation domain, enhance the levels of p300 available for p53. In apoptotic conditions, for example, caused by high levels of E2F-1 in conditions which are inappropriate for cell cycle progression or increased levels of p53 we suggest that p300 becomes limiting thus facilitating an apoptotic signal. In these circumstances, and based on the studies presented here, E2F and p53 are likely to compete for p300 leaving p53 in a transcriptionally compromised or de®cient state (Figure 10c ). However, we would like to emphasize that our data do not rule out the possibility that there are p53 target genes which need to be activated, perhaps through other co-activators, in order to achieve apoptosis. With respect to this idea, we note that p53 has been shown to utilize other co-activator molecules in transcriptional activation (Lu and Thut et al., 1995) and thus it is possible that the regulation of p53 activity by p300 relates to a speci®c group of genes.
It is noteworthy that the ability of E2F-1 to in¯uence the physiological outcome of p53 activation may bear on the phenotype of the E2F-1 knockout mice which suer thymic hyperplasia due to reduced levels of apoptosis during thymocyte ontogeny, together with an increased incidence of tumours in older animals (Field et al., 1996; Yamasaki et al., 1996) . Based on our studies, one scenario which may contribute to this phenotype in the absence of E2F-1 would be that a signal (provided by E2F-1) is lost which drives p53-dependent apoptosis, subverting the normal apoptotic process in thymocytes and thus giving rise to hyperplasia. Similarly, the loss of an apoptotic signal will encourage tumour progression, in a similar fashion to the phenotype observed in the p53 7/7 mice (Donehower et al., 1992) .
In conclusion, we have de®ned a central role for the p300 co-activator in co-ordinating the interplay between the pathways of control mediated by E2F and p53. Our data strongly support the idea that p300 functions as a negative regulator of cell cycle progression and that p300 levels are instrumental in in¯uencing whether cell cycle progression, G1 arrest or apoptosis occurs. The recent identi®cation of tumour suppressor-like mutations in p300 genes in human tumour cells provides support for such ideas (Muraoka et al., 1996) .
Materials and methods
Transfections
The following plasmids have been previously described; pCMV-pRb wt (Zamanian and La Thangue 1992) , pCMVp300 (Eckner et al., 1996) , pCMV-E2F-1 (Kaelin et al., 1992) , pCMV-p21
Waf1/Cip1 (El-Deiry et al., 1993) , pCMVbgal (Zamanian et al., 1992) , and pGal4-p53 (Fields and Jang, 1990) . To construct pTG13-GL, ®rst, the BamHI ± BglII fragment of the HSV1-tk minimal promoter element (781 to +52) was inserted to the BglII site of pXP2 vector (Nordeen, 1988) resulting in pT81-luciferase. Then, the 13 copies of the consensus p53-binding sites from pG13-CAT (Kern et al., 1992) was subcloned into the HindIII and SmaI sites of pT81-luciferase. For the Gal4 reporter construct, the Gal4 DNA binding elements and E1b TATA minimal elements from pG5E1b-CAT (Fields and Jang, 1990 ) was excised by XhoI and BamHI digestion was cloned into the pGL3 (Promega). pDHFR-luc has been described previously (Sùrensen et al., 1996) . pBax-luc and pWWP-luc were a gift from M Oren (Haupt et al., 1955b) and B Vogelstein (El-Deiry et al., 1993), respectively.
To construct pCMV-HA-DP1, three copies of HA1 epitope sequences from pGTEP-1 (a gift from B Futcher) was ampli®ed by PCR and cloned into the pCDNA3 (Invitrogen) with a consensus Kozak sequence introduced immediately 5' of the initiating ATG codon to create pCMV-HA1. The DP-1 cDNA sequence (Girling et al., 1993) in frame was introduced into pCMV-HA to generate an expression plasmid encoding an amino-terminal HA-tagged full-length DP-1.
For the mammalian two-hybrid assay, several plasmids were constructed as follows: the PCR fragment of VP16 activation domain, amino acid 423 ± 490, from Gal4-VP16 (Fields and Jang, 1990 ) was subcloned in-frame to the pCMV-HA to generate pCMV-VP16. Two p53 PCR fragments encoding amino acids 1 ± 393 and 159 ± 393 from pCMV-p53, and two E2F-1 PCR fragments encoding amino acids 1 ± 437 and 1 ± 413 from pCMV-E2F-1 were fused upstream of VP16 activation domain in pCMV-VP16 to generate pCMV-p53/VP16, pCMV-p53D159/VP16, pCMV-E2F1/VP16, and pCMV-E2F1D413/VP16, respectively. pCMV-GAD was made by the insertion of HindIII and EcoRI fragment encoding Gal4 activation domain amino acid 768 to 881, from pACT II (Clontech) into the pCDNA3. The NdeI and XbaI fragment from pCMV-E2F1 was fused inframe into pCMV-GAD to make the pCMV-GAD/E2F1. To construct pG4-p300 (611 ± 2284), the NdeI fragment from pCMV-p300 was fused in-frame to the Gal4 DNA binding domain sequence of pG4m-polyII vector (Bandara et al., 1993) . pCMV-E2F-1D413 was made by internal deletion from pCMV-E2F1. pCMV-p53 was made by the insertion of p53 cDNA from php53 (Zakut-Houri et al., 1985) into the pCDNA3. To construct the Gal4-p300 derivatives, pG4-p300 611 ± 1257 , -p300 1302 ± 1572 , -p300 1572 ± 2284 , and -p300 1572 ± 1903 were made by internal detection from pG4-p300 611 ± 2284 , respectively. Two E1A expression vectors, pCMV-E1A and pCMV-E1AD2-36 were a gift from JR Nevins (Kraus et al., 1992) .
For transfection (including¯ow cytometry), U20S and SAOS2 cells were grown in Dulbecco's modi®ed Eagles medium (DMEM) supplemented with 10% fetal calf serum (FCS). Cells were plated out 24 h before transfection at 2610 5 cells per 6 cm dish (for luciferase and b-gal assay) or 1610 6 cells per 10 cm dish (for immunoprecipitation and ow cytometric analysis). Transfections were performed by the calcium phosphate precipitation method. Whenever required, pCDNA3 or pSG5 were used to maintain a constant amount of DNA in each sample. The protein expression and stability of each construct was veri®ed by Western blotting (data not shown). Luciferase and bgalactosidase assays were performed as described previously (Jooss et al., 1995) . Each treatment was performed in duplicate. In vitro transcription and translation was carried out in a TNT T7/SP6 coupled reticulocyte lysate system (Promega).
Flow cytometry
For¯ow cytometry analysis about 10 mg of an expression vector for the cell surface protein CD20 was co-transfected into cells (grown in 10% FCS) together with 15 mg of the each expression vector for p53 or p300 (details given in Figure 8 ). Cells were washed and refed after 16 h and harvested 40 h later by washing in PBS and thereafter treating with cell dissociation medium (Sigma) for 15 min. Cells were washed in DMEM by centrifuging at 2000 r.p.m. and resuspended in a small volume of DMEM containing the anti-CD20 antibody leu16 (Becton Dickinson) coupled to¯uorescein isothiocyanate (FITC). Cells were incubated upon ice for 45 min, further washed twice in PBS and then resuspended in 50% PBS in ethanol at 208C for 30 min. Cells were collected by centrifugation and treated with RNase (125 U/ml) for 30 min, harvested by centrifugation and suspended in propidium iodide (20 mg/ ml) in PBS at 48C for 1 h. Flow cytometry was performed on a Becton Dickinson¯uorescence activated cell sorter. The intensity of propidium iodine staining was analysed in cell populations that were positive for FITC staining to determine the cell cycle pro®le of the transfected population using the Consort 30 software. The data presented show a representative example from multiple assays.
Immunoprecipitation
U2OS cells were transfected with plasmids encoding Gal4-p300, HA-DP1, E2F-1 or p53 (as indicated in ®gure legend) by the calcium phosphate procedure. After 48 h, cells were washed twice in PBS and harvested by scraping into cold TNN buer (50 mM Tris-HC1 pH 7.4, 120 mM NaCl, 5 mM EDTA, 0.5% NP40, 50 mM NaF, 1 mM DTT, 1 mM PMSF, 0.2 mM sodium orthovanedate, leupeptin (0.5 mg/ml), protease inhibitor (0.5 mg/ml), trypsin inhibitor (1.0 mg/ml), aprotinin (0.5 mg/ml) and bestatin (40 mg/ ml) and incubated on ice for 30 min. The cell extract was centrifuged for 10 min at 12 000 g and pre-cleared by incubating with protein G agarose for 1 h at 48C with constant rotation. The supernatant was harvested and 2 ml of anti-mouse Gal4 monoclonal antibody (100 mg/ml, Santa-Cruz) added for 1 h at 48C. Protein A agarose (50% v/v) was added and the incubation continued for another 1 h at 48C. The agarose beads were collected by centrifugation for 30 s at 5 000 g, the supernatant removed and the pellet washed three further times in TNN. SDS loading buer was added to the ®nal pellet, the sample denatured and loaded onto a 8~10% SDS-polyacrylamide gel. Western blotting was subsequently performed with either anti-mouse p53 (421, kindly supplied by Julian Gannon), anti-mouse HA1 (12CA5, Boehringer Mannheim), or anti-mouse E2F-1 (KH95, Santa-Cruz) monoclonal antibody.
To assess the eect of E2F-1 on p53 stability (Figure 1b ), 16 h after transfection the medium was changed and, after a further 8 h, replaced with methionine-free medium. Cells were metabolically labelled with 35 S-methionine for 1 h, washed three times, and chased for 0, 1.5, 3.0 or 4.5 h in normal medium. Cells were harvested in TNN and immunoprecipitated with the 421 monoclonal antibody. The eect of p300 on the level of p53 and E2F-1 (Figure 6 ) was assessed by performing the transfection as indicated and monitoring the level of exogenous protein by immunoblotting with either 421 or KH95.
Apoptosis assays
SAOS2 and U2OS cells were grown in serum starvation conditions on 3 cm-diameter dishes with coverslips (for TUNEL assay) or without (for cell death detection ELISA) and transfected with 4 mg of p53, E2F-1, or p300 expression plasmids. After a 16 h incubation with the precipitates, the cells were washed twice with DMEM and further incubated for 24 h in DMEM supplemented with 0.2% foetal calf serum.
For TUNEL (TdT-mediated dUTP nick end labelling) analysis, cells were washed and ®xed in 4% paraformaldehyde for 15 min at room temperature, rinsed and permeabilized in PBS cantaining 0.1% Triton X-100 and 0.1% sodium citrate for 2 min on ice. Subseqently, cells were incubated in a Ca 2+ reaction buer containinḡ uorescein-dUTP and dNTP, and terminal deoxynucleotidyl transferase (Boehringer Mannheim) at 378C for 1 h in a humid chamber. And then, cells were further incubated in DAPI (2 mg/ml, Sigma) for DNA staining. Cover slips were washed three times in PBS, mounted, and viewed under thē uorescence microscope.
